Goldman Sachs Group Inc Nuvation Bio Inc. Transaction History

Goldman Sachs Group Inc

  • $613 Billion
  • Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,029,774 shares of NUVB stock, worth $3.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,029,774
Previous 1,324,170 53.29%
Holding current value
$3.8 Million
Previous $3.05 Million 77.31%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
BUY
$2.01 - $3.01 $1.42 Million - $2.12 Million
705,604 Added 53.29%
2,029,774 $5.4 Million
Q3 2024

Nov 14, 2024
BUY
$2.3 - $3.83 $424,727 - $707,263
184,664 Added 16.21%
1,324,170 $3.05 Million
Q2 2024

Aug 13, 2024
SELL
$2.58 - $3.69 $825 - $1,180
-320 Reduced 0.03%
1,139,506 $3.33 Million
Q1 2024

May 15, 2024
BUY
$1.46 - $3.97 $504,748 - $1.37 Million
345,718 Added 43.54%
1,139,826 $4.15 Million
Q4 2023

Feb 13, 2024
BUY
$0.96 - $1.53 $366,292 - $583,779
381,555 Added 92.49%
794,108 $1.2 Million
Q3 2023

May 14, 2024
SELL
$1.26 - $2.1 $480,759 - $801,265
-381,555 Reduced 48.05%
412,553 $552,000
Q3 2023

Nov 14, 2023
SELL
$1.26 - $2.1 $112,069 - $186,782
-88,944 Reduced 17.74%
412,553 $552,000
Q2 2023

May 14, 2024
BUY
$1.56 - $1.84 $161,235 - $190,175
103,356 Added 25.96%
501,497 $902,000
Q2 2023

Aug 14, 2023
BUY
$1.56 - $1.84 $161,235 - $190,175
103,356 Added 25.96%
501,497 $902,000
Q1 2023

May 14, 2024
BUY
$1.6 - $2.48 $251,185 - $389,337
156,991 Added 65.1%
398,141 $660,000
Q1 2023

May 11, 2023
BUY
$1.6 - $2.48 $251,185 - $389,337
156,991 Added 65.1%
398,141 $660,000
Q4 2022

May 14, 2024
SELL
$1.68 - $2.5 $509,370 - $757,992
-303,197 Reduced 55.7%
241,150 $463,000
Q4 2022

Feb 13, 2023
SELL
$1.68 - $2.5 $509,370 - $757,992
-303,197 Reduced 55.7%
241,150 $463,000
Q3 2022

May 14, 2024
BUY
$0.29 - $4.04 $115,797 - $1.61 Million
399,301 Added 275.29%
544,347 $1.22 Million
Q3 2022

Nov 10, 2022
BUY
$0.29 - $4.04 $115,797 - $1.61 Million
399,301 Added 275.29%
544,347 $1.22 Million
Q2 2022

May 14, 2024
SELL
$3.24 - $5.85 $2.1 Million - $3.8 Million
-649,062 Reduced 81.73%
145,046 $470,000
Q2 2022

Aug 15, 2022
SELL
$3.24 - $5.85 $1.85 Million - $3.34 Million
-571,399 Reduced 79.75%
145,046 $470,000
Q1 2022

May 16, 2022
BUY
$4.6 - $8.83 $2.62 Million - $5.03 Million
569,597 Added 387.88%
716,445 $3.77 Million
Q4 2021

Feb 14, 2022
BUY
$7.75 - $10.05 $713,581 - $925,353
92,075 Added 168.1%
146,848 $1.25 Million
Q3 2021

Nov 10, 2021
BUY
$7.78 - $10.0 $426,133 - $547,730
54,773 New
54,773 $545,000

Others Institutions Holding NUVB

# of Institutions
163
Shares Held
151M
Call Options Held
1.2K
Put Options Held
223K
View Full List

About Nuvation Bio Inc.

NUVB Quotes by TradingView
  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $406M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email